Ginkgo Bioworks Holdings (DNA) Stock Forecast: StockMap's 2-Week Call
DNA stock forecast: StockMap's model makes no two-week call on Ginkgo Bioworks Holdings after the Nov 19 close: its evidence is split, 3 reasons for and 12 against. Right in 1 of 4 two-week windows on DNA since Aug 21; by chance, a call on the same dates was right 69% of the time.
Ginkgo Bioworks Holdings last closed at $8.20, -2.84% on the session.
Against the IVW growth benchmark the position is -0.51% over the forecast window.
Ginkgo Bioworks Holdings' market cap is $506.98M as of November 19, 2026.
No call today: the model sees no clear direction · the next 2 weeks, vs S&P 500 growth. The lean on a scale from −100 to +100 is 3 (too close to call).
Where DNA sits: sized by market cap, coloured by the day's move.
The read is built from 15 underlying insights — 3 bullish and 12 bearish.
Agreement across those insights is 20%.
28 daily calls for DNA so far. We publish our accuracy across thousands of stocks in the open, misses included — no per-stock hit rate is claimed on a small sample.
On the fundamentals StockMap ranks Ginkgo Bioworks Holdings in the 16th percentile on return on equity, where 100 is best.
Ginkgo Bioworks Holdings is classified under Health Care / Life Sciences Tools & Services.
StockMap tracks Ginkgo Bioworks Holdings as the 35th largest of the 42 companies it covers in the Life Sciences Tools & Services industry, part of the Health Care sector.
Across that group the current two-week reads are 23 Neutral, 16 Moderate Outperform and 3 Moderate Underperform.
On that composite Ginkgo Bioworks Holdings ranks 31st of 42 in the group, against a group median of +0.13.